A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Hafnium oxide (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Oesophageal cancer
Focus Adverse reactions
Sponsors Nanobiotix

21 May 2024 According to a Nanobiotix media release,Dose escalation part ongoing,the company expected to complete dose escalation part and initiation of dose expansion part in this year. first data will be presented in 2025.
13 Nov 2023 According to a Nanobiotix media release, determination of RP2D in NSCLC trial, Completion of enrollment in Phase 1b dose expansion trial in pancreatic cancer, Initial Phase 1b/2 data in esophageal cancer data expected in 2024.
08 Nov 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com